安罗替尼联合AP方案治疗晚期非小细胞肺癌的临床研究

Clinical study on anlotinib combined with AP chemotherapy regimen in treatment of advanced non-small cell lung cancer

目的考察盐酸安罗替尼胶囊联合AP方案(注射用培美曲塞二钠和顺铂注射液)治疗晚期非小细胞肺癌的临床疗效。方法选取2018年8月—2019年8月在漯河市郾城区人民医院治疗的80例晚期非小细胞肺癌患者,将所有患者随机分为对照组和治疗组,每组各40例。对照组患者采用AP方案,第1天静脉滴注注射用培美曲塞二钠,推荐剂量为500 mg/m2,溶于100 mL生理盐水中,滴注时间为30 min,在静注结束之后30 min静脉滴注顺铂注射液,推荐剂量为75 mg/m2,溶于500mL生理盐水中,滴注时间为200min。治疗组患者在对照组基础上口服盐酸安罗替尼胶囊,1粒/次,1次/d。21d为1个治疗周期,两组接受治疗2个治疗周期。观察两组患者临床疗效,比较两组的无病生存期(PFS)、总生存期(OS)、卡氏功能量表(KPS)评分、肺癌生存质量评价量表(FACT-L)评分、血清肿瘤标志物水平。结果治疗后,对照组客观缓解率(ORR)和疾病控制率(CBR)分别为50.00%、62.50%;治疗组ORR和CBR分别为65.00%、80.00%;治疗组显著较高(P<0.05)。治疗后,治疗组患者PFS和OS明显高于对照组(P<0.05)。治疗后,两组KPS评分和FACT-L评分显著升高(P<0.05),且治疗组KPS评分和FACT-L评分明显高于对照组(P<0.05)。治疗后,两组血清癌胚抗原(CEA)、糖类抗原125(CA125)、糖类抗原199(CA199)水平均显著降低(P<0.05);且治疗组血清CEA、CA125、CA199水平明显低于对照组(P<0.05)。结论盐酸安罗替尼胶囊联合AP方案治疗晚期非小细胞肺癌具有较好的治疗效果,能够提高患者生活质量,降低血清肿瘤标志物水平。

Objective To investigate the efficacy of Anlotinib Hydrochloride Capsules combined with AP chemotherapy regimen(Pemetrexed Disodium for injection combined with Cisplatin Injection)in treatment of advanced non-small cell lung cancer.Methods Patients(40 cases)with advanced non-small cell lung cancer in Luohe Yancheng District People’s Hospital from August 2018 to August 2019 were randomly divided into control and treatment groups,and each group had 40 cases.Patients in the control group were treated with AP chemotherapy regimen,and iv administered with Pemetrexed Disodium for injection at first day,the recommended dosage 500 mg/m^2 added into normal saline 100 mL,and the infusion time was 30 min.After the end of intravenous injection for 30 min,the recommended dosage was 75 mg/m^2 added into normal saline 500 mL,and the infusion time was 200 min.Patients in the treatment group were po administered with Anlotinib Hydrochloride Capsules on the basis of the control group,1 grain/time,once daily.A treatment cycle had 21 d,and patients in two groups were treated for 2 treatment cycles.After treatment,the clinical efficacies were evaluated,and PFS,OS,KPS score,FACT-L score,and serum tumor markers in two groups were compared.Results After treatment,the ORR and the CBR of the control group were 50.00%and 62.50%,respectively,and the ORR and the CBR of the treatment group were 65.00%and 80.00%,respectively,and the indexes of the treatment group was significantly higher than those of the control group(P<0.05).After treatment,the PFS and the OS of the treatment group were significantly higher than those of the control group(P<0.05).After treatment,KPS score and FACT-L score of two groups were significantly increased(P<0.05),and KPS score and FACT-L score of the treatment group were significantly higher than those of the control group(P<0.05).After treatment,the serum levels of CEA,CA125,and CA199 in two groups were significantly decreased(P<0.05),and the serum levels of CEA,CA125,and CA199 in the treatment group were significantly lower than those in the control group(P<0.05).Conclusion Anlotinib Hydrochloride Capsules combined with AP chemotherapy regimen has clinical curative effect in treatment of advanced non-small cell lung cancer,can improve the quality of life of patients,and reduce the serum level of tumor markers.